An interventional study of New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery in Neoplasms, Adenocarcinoma and Carcinoma, sponsored by Imperial College London. Recruiting at 4 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Adenocarcinoma with a site in United Kingdom — 9 open to participants now, 15 under way, 5 of them phase 3. Adenocarcinoma · United Kingdom.
Among the 53 studies in Adenocarcinoma with a site in United Kingdom, this one is the 18th largest by planned enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2014, is one of 6 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 28th registered.
622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.
Browse Adenocarcinoma studies →9 of the 53 studies in Adenocarcinoma with a site in United Kingdom are open now. Recruiting first, the newest first:
University College, London · Sites in United Kingdom
Ages 18+ · Men only
AstraZeneca · Sites in United Kingdom, United States, Australia and 21 more countries
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United Kingdom, United States, Australia and 19 more countries
Ages 18+
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Ages 18–75 · Men only
Imperial College London · Sites in United Kingdom
Ages 18+ · Men only
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 113 Adenocarcinoma studies recruiting now, 84 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 19 · Phase 3 15 · Phase 4 3
First in 2001; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 383 is above the median of 57 across 492 interventional studies indexed under Adenocarcinoma.
Median enrollment 260 across the 49 interventional studies, 210 across the 4 observational. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 53 have an industry lead sponsor. The 10 most frequent:
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Imperial College London has 2 studies filed under Adenocarcinoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Adenocarcinoma with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02292641Imperial College LondonBeyond TME Origins | 2026-12 |
| NCT02973828Institute of Cancer Research, United KingdomPRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy | 2026-12-31 |
| NCT05873686Nuvectis Pharma, Inc.A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | 2027-03 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Adenocarcinoma with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk factors for recurrence. We will record treatment for the recurrence, and patients will be followed up for three years.
A prospective and retrospective cohort study to improve surgical and treatment planning using an imaging assessment proforma of advanced and recurrent colorectal cancers. This involves the implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.
622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.
This study's planned enrollment of 383 is above the median of 57 across 492 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Compared within Adenocarcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Implementation of imaging assessment proformas describing anatomic pelvic compartments and aetiology of disease recurrence for treatment planning.
Procedure: New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
To change R0 resection rates for locally recurrent rectal cancers with the use of the proposed staging system.
An increase of 20% in R0 resection (from 55% to 75%) for locally recurrent rectal cancers with the use of the proposed staging system
Time frame: 3 years
To compare baseline prognostic features against type of recurrence
Correlation of baseline and post treatment prognostic factors on imaging and pathology against type of recurrence.
Time frame: 3 and 5 years
To compare the MRI type of recurrence against clinical outcomes
Proportion of patients with survival \>12mths according to type of recurrence as described on MRI
Time frame: 1, 3 and 5 years
To compare the MRI compartment(s) distribution of recurrence against clinical outcomes
Proportion of patients with survival \>12mths according to compartment(s) of recurrence as described on MRI
Time frame: 1, 3 and 5 years
To investigate the effect of surgical and non-surgical treatments for recurrence on Quality of Life
Quality of life assessed using EORTC QLQ-C30
Time frame: 1, 2, 3 and 5 years
To compare radiology and histopathology compartments in patients undergoing beyond TME surgery for recurrence
The number of compartments predicted as involved on MRI against the number of compartments reported on the corresponding pathology specimens
Time frame: Up to 2 years
To measure radiology inter-observer agreement for types of recurrence classification
Kappa agreement between paired radiologists for type of recurrence
Time frame: 5 years
To investigate health economic costs of patients with pelvic recurrence against type
Healthcare costs using NHS Reference Costs combined with health resource utilization and QoL data
Time frame: Up to 3 years
To map original radiotherapy volumes (including integrated boosts) against types of recurrence
Correlation of dose, type and distribution of radiotherapy against anatomic sites and aetiology of recurrence as seen on MRI
Time frame: Up to 2 years
Started Sep 2014 (actual). Primary completion is estimated for Dec 2026, 147 months after the start.
Of 41 interventional studies with no phase under Adenocarcinoma, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 170. This study's planned 147 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.